Neuren Pharmaceuticals hopes to develop long-term treatment for newborn brain injury

Neuren Pharmaceuticals hopes to develop long-term treatment for newborn brain injury
Neuren Pharmaceuticals chief executive Jon Pilcher says the Kiwi firm is in a privileged position. (Image: Neuren Pharmaceuticals)
Rebecca Stevenson
Neuren Pharmaceuticals' boss Jon Pilcher says he was punching the air after leaving a recent successful meeting with the US Food and Drug Administration.Neuren, a local company which develops treatments for neurological disorders including Rett syndrome, has been cleared to begin phase-three trials for the drug NNZ-2591 to treat Phelan-McDermid syndrome. It will be the first-ever phase-three trial in children with the rare genetic condition.The disorders Neuren targets for treatment with its drugs are often debilitating and can ha...

More Markets

Vulcan Steel leads as reporting season approaches
Markets Market Close

Vulcan Steel leads as reporting season approaches

The S&P/NZX 50 Index closed 55.30 points higher at 12,889.38.

Jamie Gray 15 Aug 2025
Competition law changing to allow 'beneficial collaboration'
Markets

Competition law changing to allow 'beneficial collaboration'

Confidential submissions to the Commerce Commission will get a 10-year OIA exemption.

Pattrick Smellie 15 Aug 2025
Small cap spotlight: Blackpearl Group
Markets Small Cap Wrap

Small cap spotlight: Blackpearl Group

Founder Nick Lissette says it's patriotic to be listed, but hard work.

NZ sharemarket rises, Vista Group shares fall
Markets Market Close

NZ sharemarket rises, Vista Group shares fall

The New Zealand sharemarket was up on Thursday as most stocks on the main board lifted.

Tom Raynel 14 Aug 2025